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Abstract

Postural orthostatic tachycardia syndrome (POTS) is a common yet frequently
misdiagnosed dysautonomia characterized by a significant increase in heart rate upon
standing. POTS patients experience severe fatigue, dizziness, pre-syncope, and a
diminished quality of life. The intent of this thesis is to investigate factors contributing to
POTS misdiagnosis and develop a proposal for improving diagnostic procedures. The first
part of this thesis presents an overview of other frequently misdiagnosed conditions,
providing an understanding of the basis for the diagnostic problems in POTS and methods
to combat such difficulties. The second part of this thesis details a meta-analysis performed
on POTS clinical studies since its classification in 1993, in an attempt to synthesize current
knowledge and potential deficits in research. Results show the misdiagnosis rates for POTS
are understandably high, as POTS shares many characteristics with other misdiagnosed
conditions. Analysis of these conditions demonstrates the need for easier in-clinic
diagnostic tests for POTS. The meta-analysis results demonstrate misunderstanding about
POTS remains within the scientific community. The final recommendations to reduce POTS
misdiagnosis include using a blood pressure/heart rate screening test to identify patients
sooner and shifting research efforts from etiology and treatment to prevalence and
diagnostic procedures.

ii

Acknowledgments
I would like to express my very great appreciation to my thesis chair, Dr. Robert Borgon,
and my thesis committee members, Dr. Mohtashem Samsam and Dr. Maureen Covelli, for
their constant support throughout this process. Their time, ideas, and constructive
suggestions were invaluable to the completion of this thesis.
I would also like to thank the professors and staff of the Burnett Honors College for their
guidance throughout the entire Honors in the Major process.

iii

Table of Contents
Chapter One: Introduction................................................................................................................................. 1
An Overview of Postural Orthostatic Tachycardia Syndrome ........................................................ 1
Diagnosis and Misdiagnosis ......................................................................................................................... 2
Chapter Two: Literature Review ..................................................................................................................... 5
Symptoms ............................................................................................................................................................ 5
Pathophysiology ............................................................................................................................................... 6
Psychological Component .......................................................................................................................... 11
Treatment and Intervention ..................................................................................................................... 13
Chapter Three: Objectives .............................................................................................................................. 15
Identification of Problem ........................................................................................................................... 15
Proposed Research ....................................................................................................................................... 16
Chapter Four: Examination of Other Frequently Misdiagnosed Conditions ............................... 18
Overview ........................................................................................................................................................... 18
Literature Review ......................................................................................................................................... 18
Common Themes ........................................................................................................................................... 28
Chapter Five: Meta-Analysis on POTS ........................................................................................................ 31
Methodology ................................................................................................................................................... 31

iv

Results ............................................................................................................................................................... 32
Discussion ........................................................................................................................................................ 38
Chapter Six: Future Research ........................................................................................................................ 43
Chapter Seven: Conclusion ............................................................................................................................. 45
Appendix A: Meta-Analysis ............................................................................................................................ 49
Appendix B: Future Research ........................................................................................................................ 57
References ............................................................................................................................................................ 59

v

List of Figures
Figure 1: PubMed Review: References to POTS by Year..................................................................... 33
Figure 2: PubMed Meta-Analysis: POTS Clinical Studies by Year ................................................... 34
Figure 3: Terminology Used for POTS ....................................................................................................... 35

vi

List of Tables
Table 1: POTS Symptoms ................................................................................................................................... 5
Table 2: CARE Method...................................................................................................................................... 20
Table 3: Summary of Examination of Misdiagnosed Conditions ..................................................... 30
Table 4: Meta-Analysis Impact Factors ..................................................................................................... 36
Table 5: Categories of Clinical Studies ....................................................................................................... 37
Table 6: Categories of Non-Pharmacologic Treatment ....................................................................... 37
Table 7: Categories of Pharmacologic Treatment ................................................................................. 38
Table 8: Meta-Analysis Summary ................................................................................................................ 50

vii

Chapter One: Introduction

An Overview of Postural Orthostatic Tachycardia Syndrome

Postural orthostatic tachycardia syndrome (POTS) is a defect of the autonomic
nervous system in which patients present with rapid heart rate upon standing, and a
subsequent inability to tolerate orthostatic posture for long periods.56 Physiologically, the
condition is characterized as a form of autonomic neuropathy leading to insufficient
peripheral vasculature constriction when adopting an upright (orthostatic) posture; the
associated tachycardia is assumed to be a mechanism for maintaining appropriate blood
pressure and organ perfusion when in such a position.64 As POTS is a nervous system
deficit, its associated symptoms are diverse, manifesting as cardiology, gastrointestinal,
and pulmonary complications.19 Though often initially misdiagnosed as a psychological
problem, symptoms in POTS patients have been proven to be physiological rather than
psychological.4
Although misunderstood and under-recognized, POTS is actually a fairly prevalent
disorder,19 currently impacting 500,000 individuals in the United States; due to the low
rates of diagnosis, however, some estimate as many as 3 million may actually be afflicted
nationally.4, 29, 65, 71 POTS is known to affect females at a rate five times higher than that of
males; among these impacted women, the vast majority are of childbearing age
(approximately 15-40 years of age).19, 67 Interestingly, many report that the onset of their

POTS symptoms began after a specific event, such as a viral infection, pregnancy, surgery,
or trauma. Although the mechanism behind this correlation is not confirmed, it has been
postulated that significant blood loss is to blame in these situations, exacerbating already
existing hypovolemia (decreased blood volume).67 Most patients and physicians report a
significant diminishment in health-related quality of life after the onset of POTS, with many
in the medical community characterizing the condition as debilitating.65 Some patients are
unable to attend work or school due to the severity of their symptoms; estimates suggest
up to 25% of POTS patients are functionally disabled.8 Daily life tasks such as chores and
bathing often lead to incapacitating fatigue, leading to a quality of life comparable to those
with congestive heart failure.67

Diagnosis and Misdiagnosis

POTS is diagnosed following evidence of an increase in heart rate of 30 bpm in
adults or 40 bpm in teenagers after transitioning from a supine to standing position,
without indications of orthostatic hypotension (decrease in blood pressure on standing).19,
68

The use of the tilt table test is encouraged when diagnosing POTS, as the patient’s heart

rate, blood pressure, and EKG recordings can be completed while the patient is closely
monitored and raised from a supine to upright position.65 Additionally, the use of a table
and restraints prevents the patient from utilizing somatic movements of the limbs to
increase venous return and distort vital signs.53 The use of blood work and a detailed
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history in conjunction with the tilt table test can help ensure that the patient’s symptoms
are not a result of other medical conditions, such as neurogenic orthostatic hypotension,
autonomically mediated syncope, hyperthyroidism, dehydration, or anemia, or due to
medications such as oral contraceptives, anti-depressants, vasodilators, or diuretics.65 Such
conditions and medications can cause an inability to tolerate orthostatic posture; however,
tilt-table testing will not demonstrate an increase of heart rate of 30 bpm without a change
in blood pressure when upright in these patients.
Unfortunately, POTS diagnoses are rarely this simple. In general, 83% of those with
a form of dysautonomia are initially misdiagnosed with anxiety or panic disorders, a trend
seen with POTS patients as well; some have even been diagnosed with conditions as
unrelated as pneumonia.65, 67 An overall lack of physician awareness is predominantly to
blame, further complicated by its recent characterization. POTS was only clinically
described in 1993, thus health care providers trained prior to the nineties are unlikely to
have been exposed to the syndrome. Most believe, however, that early references to heart
conditions such as irritable heart syndrome, soldier’s heart, Da Costa syndrome, effort
syndrome, and idiopathic tachycardia syndrome throughout the last century were
indicative of early misdiagnosed POTS patients.65 Even today, some references to POTS
utilize the phrases “postural tachycardia” or “chronic orthostatic intolerance.” Such naming
discrepancies have likely contributed to misdiagnoses and clinical confusion as well.29 As
such, the average time from onset of symptoms to a POTS diagnosis is six years.65 Reaching
this diagnosis, however, is critical for the patient’s health and symptom management; one
Mayo study found that after accurate diagnosis and appropriate treatment, 80% of POTS
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patients improved, with as many as 60% reaching a near-normal quality of life.76 Thus,
studying ways to reduce the high rate of misdiagnosis of POTS is critical; patients can
usually manage symptoms successfully once a correct diagnosis has been made.
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Chapter Two: Literature Review

Symptoms

The most commonly identified symptoms in POTS patients include:19, 67
Table 1: POTS Symptoms

Excessive fatigue
Nausea
Dyspnea
Headache
Abnormal sweating
Weakness

Lightheadedness
“Brain Fog”
Numbness of extremities
Exercise intolerance
GI problems
Tremulousness

Difficulty standing still
Heart palpitations
“Pins and needles”
Heat intolerance
Cyanosis in feet
Unrefreshing sleep

The most frequently reported symptom is a debilitating level of fatigue, shown to be
three times higher in POTS patients than healthy members of society. A lack of deep sleep
and high prevalence of sleep disorders in POTS patients likely contributes to this fatigue,
resulting in a high level of daytime exhaustion.4 Research shows sleep in POTS may be as
impaired as that seen in chronic fatigue syndrome. Physical signs of orthostatic intolerance,
including dizziness and lightheadedness, are also commonly reported; transitioning to a
supine position moderately reduces symptoms by relieving this orthostatic stress.56
Additionally, patients may develop subconscious mechanisms when standing to further
compensate for decreased venous return.53 While almost all POTS patients experience
feelings of pre-syncope due to this orthostatic intolerance, not all experience true syncope,
and fainting is certainly not a necessity for a POTS diagnosis.81 Finally, about 50% of POTS
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patients report acrocyanosis, reddish-blue coloring seen in lower limbs upon standing,
though the reasoning behind this has yet to be determined.65, 67
POTS is often seen with autoimmune or connective tissue disorders, and patients
may be double-jointed, indicative of Ehlers-Danlos syndrome.19 Other conditions
commonly comorbid with POTS include amyloidosis, celiac disease, chronic fatigue
syndrome, diabetes, fibromyalgia, migraines, mitochondrial disease, and multiple
sclerosis.65

Pathophysiology

Identifying the underlying cause for POTS has proven to be a challenge for both
researchers and physicians. In all cases, the true pathology seems to lie in a defect of the
autonomic nervous system; however, the manner in which this deficit manifests itself and
impacts the individual varies. This variety in clinical manifestation likely contributes to a
high rate of POTS misdiagnosis, though all causes are essentially interconnected along a
continuum of ANS-mediated dysfunctions.65
The physiological basis for many of the symptoms presenting in POTS patients have
been elucidated, however. For example, diminished blood flow to the cerebral cortex as a
result of both hypovolemia and venous pooling leads to the “mental cloudiness” or “brain
fog” symptom.1 Sleep disorders have been shown to be associated with dysfunction of the
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autonomic nervous system, suggesting an explanation for the chronic fatigue and lack of
refreshing sleep in POTS.4 Additionally, the tachycardia seen upon standing has been
proven to originate from the sinoatrial node; if a patient’s tachycardia does not meet this
requirement, POTS can be ruled out.67
Below, the main physiological origins discussed for POTS in the literature are
outlined. In addition to these, autoimmune dysfunction, mast cell activation, and
deconditioning have been proposed.18 Research shows low iron storage capabilities leading
to mild anemia is common in POTS patients as well; whether or not this anemic state is a
cause or result of the illness has yet to be elucidated.44 As aforementioned, however,
current literature tends to agree all “causes” are essentially manifestations of an underlying
ANS defect, and are not truly distinct; denervation that impacts specific muscle and organ
systems is nearly always to blame.65

Hypovolemic POTS

Most POTS patients present with some degree of hypovolemia. When compared to
healthy individuals, POTS patients’ plasma volume was an average of 13% less than ideal
for their stature; in extreme cases, a deficit as high as 27% was seen.65, 67, 68 This
hypovolemia leads to POTS symptoms through what some researchers have called the
renin-aldosterone paradox.67 In a normal patient, hypovolemia would signal an increase in
renin, and subsequently angiotensin I, angiotensin II, and aldosterone, in an attempt to
7

increase blood volume.68 This mechanism would stimulate the reabsorption of sodium and
water in the nephron, thus improving hypovolemia and subsequent hypotension. However,
POTS patients have significantly lower serum aldosterone and inappropriately low renin
activity despite their degree of hypovolemia.65, 68 This deficit leads to an inability to retain
sodium and water in an attempt to raise blood volume and blood pressure; as a result, a
corresponding decrease in cardiac stroke volume means an increased heart rate is the only
mechanism capable of maintaining cardiac output, resulting in tachycardia. Finally, while
research shows 50% of POTS patients state a viral infection preceded the onset of their
symptoms, most believe such traumas simply exacerbate already existing hypovolemic
conditions.76

Neuropathic POTS

Studies have indicated 50% of POTS patients have partial sympathetic denervation,
or a partial dysautonomia, in the lower limbs.65, 68 Upon standing, blood typically shifts to
the lower limbs and pools under the influence of gravity; however, in a healthy patient, the
body can quickly correct this imbalance with peripheral smooth muscle contraction to
return blood to the heart and major organ systems. In POTS, however, this lower limb
denervation leads to venous pooling in the legs; venous return to the heart decreases, and
the body responds with an increase in heart rate to maintain cardiac output.65 This POTS
pathology is the most likely reasoning behind the “difficulty standing still” phenomenon.
8

Internal physiological discomfort as a result of venous pooling and resultant tachycardia
may lead to the fidgeting, leg tensing, and other unconscious maneuvers that POTS patients
sometimes demonstrate. These counter maneuvers are meant to increase venous return to
the heart through contraction of skeletal muscles, which aids in venous return.

Hyperadrenergic POTS

POTS patients also show levels of norepinephrine twice as high as controls after
assuming a standing position.65, 68 This increase in norepinephrine is thought to be a
mechanism to compensate for the aforementioned hypovolemia and peripheral
denervation.65 These hyper adrenergic levels lead to tachycardia, tremulousness, anxiety,
and heart palpitations, as seen in POTS. Although rare, it seems that in some patients this
increase may be due to a genetic deficiency in norepinephrine reuptake. A single point
mutation in the SLC6A2 norepinephrine transport protein leads to a decreased ability in
clearing the hormone from synaptic clefts, and has been identified in some POTS patients.64

Deconditioned POTS

A slightly controversial study by Fu et al claims POTS is not due to an ANS disorder
as commonly cited, but solely due to hypovolemia and cardiac atrophy. Findings of
9

decreased heart mass in sufferers of chronic fatigue syndrome and reported overlaps
between this disorder and POTS prompted their research, which found reduced left
ventricular mass in POTS patients when compared to controls. Based on a hypothesis that
this atrophy was due to deconditioning, an exercise regimen featuring low-orthostatic
stress routines (recumbent biking, rowing, and swimming) was implemented, which
successfully increased heart size, mass, and volume. By the end of the program,
participants could reportedly walk and jog without stress. Due to the potential
pathological effects of this decreased heart size, Fu et al propose renaming of POTS to “The
Grinch Syndrome.”4

Genetics

Research shows genetic inheritance may play a role in the development of POTS,
with up to 20% of patients showing indications of a family history of the condition.64
Studies show many children with POTS demonstrate variations of the GNB3 gene C825T,
which leads to changes in the G protein B3 subunit that serves as a component of the
autonomic nervous system.60 These polymorphisms lead to an increase in heart rate upon
standing, and could represent a definitive cause for the dysautonomia behind POTS.
Additionally, as mentioned, a defect in the SLC6A2 norepinephrine transport protein has
also been indicated, leading to a hyperadrenergic state.64 Finally, POTS patients are more
likely to have genetic polymorphisms in the nitric oxide synthetase gene NOS3, which could
10

explain changes to blood flow in the condition.35 While a number of possible genetic causes
have been identified, further research is needed to determine which variations are most
significant in the onset of POTS.

Psychological Component

As discussed, POTS patients are frequently misdiagnosed with psychological
illnesses such as anxiety or panic disorder prior to their POTS treatment, likely due to
symptoms such as heart palpitations, shortness of breath, and faintness.64, 67 Studies based
on criteria presented in the Diagnostic and Statistical Manual of Mental Disorders,
however, show POTS patients do not have higher prevalence of depressive, anxiety, or
substance abuse disorders than the general population. While some have reported high
anxiety levels in POTS patients through the use of the Beck Anxiety Inventory scale, this
index utilizes somatic as well as psychological indicators of anxiety, and thus over-predicts
the prevalence of anxiety in POTS patients whose hyper-adrenergic states likely alter test
results. When assessed with solely psychological measures, such as the Anxiety Sensitivity
Index, anxiety levels were not higher than the general population.71 In fact, studies have
found that mental health was the only health indicator in which POTS patients did not
score worse than controls from the general public.5
Although POTS is defined as a physiological disorder, stress can be a trigger that
exacerbates symptoms.18 As such, some still claim psychological factors are important to
11

consider when treating POTS patients, with adolescents in particular being at risk for
increased stress and mental health disorders. Since life with POTS can mirror disabilities
such as chronic pain and diabetes, researchers such as McTate et al have begun to explore
the effectiveness of pain rehabilitation based treatment programs and claim moderate
success.56

Prevalence in Women

As mentioned, POTS is far more prevalent in women than in men, with an incidence
rate five times higher in females.19 Such epidemiological differences have led to research
aimed at investigating why most POTS sufferers are female. It is theorized that estrogen
and progesterone, which play a role in RAAS regulation and maintenance of blood volume,
could be related to the higher female prevalence.66, 88 Although many POTS patients report
worsening of symptoms during their menstrual periods, research has not shown any
change or dysfunction in the activity of the sympathetic nervous system in menstruating
female POTS patients.88 Instead, natural changes in blood pressure may be involved in
increased orthostatic intolerance during menstruation.88 Healthy women also report
lightheadedness during menses, suggesting menstruation may not play a significant role in
POTS.66 Although hypovolemia does seem to impact women to a greater extent than men,
with studies demonstrating increased susceptibility to hypovolemic stress in females, no
definitive link between sex-related hypovolemia and POTS has been confirmed.49
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Treatment and Intervention

For many patients, pharmacological intervention represents an important step in
symptom management. Treatments like salt supplementation and fludrocortisone target
hypovolemia by increasing water and sodium retention and enhancing venous return,
while midodrine acts as a norepinephrine agonist to induce vasoconstriction.65, 67 Research
has shown that such plasma volume expanders can lead to long-term improvement.68
Frequently, however, patients are unable to tolerate the side effects of these drugs.4
Additionally, while drugs are designed to mitigate symptoms, they are unable to treat the
underlying sympathetic denervation assumed to the primary cause of POTS. When
pharmacological intervention fails, patients can learn to manage their symptoms through
simple strategies and avoidance behaviors. As mentioned, an increase in dietary salt intake
is recommended, as well as the use of compression stockings to aid in venous return and
frequent hydration to combat hypovolemia. Large meals should be avoided, as an increased
volume of blood will be drawn to the intestines during digestion; instead, smaller meals
and snacks should be eaten throughout the day. Other exacerbating conditions, such as
heat, alcohol, and dehydration, should be avoided as well.65
Exercise training is highly recommended due to its ability to increase blood volume
and train muscles to improve venous return.29, 67 Unfortunately, even mild exercise
worsens symptoms; patients can feel debilitating weakness and fatigue for days after
physiological stress.8, 67 As a compromise, low-intensity exercise that does not exacerbate
orthostatic intolerance symptoms should be used, such as swimming, rowing, and
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recumbent biking. Yoga and Pilates are frequently advised as well, and often met with
success.29, 65
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Chapter Three: Objectives

Identification of Problem

A review of the medical literature surrounding POTS suggests that a focus on
improving clinician awareness and diagnostic procedures should be the primary approach
to combat this disorder. Various teams have attempted to determine the physiological basis
of this syndrome, but a correct understanding of the origin of POTS has limited practicality
if existing rates of misdiagnosis are not improved. In most cases, the cause of a patient’s
POTS is unknown, and the physician will proceed with a similar set of standardized
treatments rather than attempt to determine the pathology surrounding their condition
anyway; furthermore, even when a cause is suspected, targeted drug therapy is often
intolerable. It seems that for most cases, treatment of POTS is reduced to symptom
management; thus, the critical step in any patient’s recovery is simply an accurate POTS
diagnosis, enabling them to understand techniques to alleviate symptoms and avoid
exacerbating their condition.
As discussed, POTS is diagnosed after evidence of an increase in heart rate of at least
30 bpm after transitioning from a supine to standing position, and the tilt table test
represents the best technique to observe this phenomenon. Patients can be closely
monitored, and the fixed positioning of the patient to the table prevents unconscious
compensatory movements developed to increase venous return and alleviate discomfort,
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such as contraction of lower limb muscles to supplement the mechanism of the skeletal
muscle pump. A variety of difficulties unfortunately prevent this procedure from being
widely implemented. The tilt table test can cost patients upwards of $6000, with no
guarantee of insurance coverage even when patient presentation indicates POTS.
Additionally, primary care physicians likely lack access to such equipment, requiring a
referral to a hospital or specialized clinic. Finally, the tilt table test is considered inherently
hazardous for the patient, as it provokes cardiovascular symptoms and brings the patient
near syncope.14 Such problems with the tilt table test, combined with overall lack of
physician awareness and understanding, potentially contribute to the slow rates of
diagnosis.
Due to the aforementioned complications, reduction in the misdiagnoses of POTS
patients is doubtful without medical education on the condition and widespread
implementation of an easier method to identify POTS candidates. The goal of this thesis is
to synthesize information from existing literature in order to develop a proposal for
reducing the misdiagnosis rate based on these assumptions.

Proposed Research

The goal of this thesis is to develop a proposal for reducing both the high rate of
misdiagnosis for POTS and the time it takes for patients to receive accurate diagnosis. As
mentioned above, a critical part of such an endeavor is the identification of an easier way to
16

identify POTS patients. Research on how this can be accomplished will continue with a twopart project, as described below.

Part One: Examine methods used with other frequently misdiagnosed conditions
Part Two: Examine current research trends on POTS through a meta-analysis

Again, as described, implementation of a simple way to identify POTS patients is
ideal, but cannot happen without first increasing clinician awareness. For this reason, an
extended literature review on other frequently misdiagnosed conditions (Part One) will be
performed to gain insight on methods successfully used to increase physician
understanding and facilitate accurate diagnoses. Disorders planned to study include
thyroid dysfunction, fibromyalgia, Lyme disease and Lupus. Next, a meta-analysis on
current research being performed on POTS will be performed. This analysis serves two
functions. First, the meta-analysis will provide an understanding of where the scientific
community currently is in terms of awareness and diagnosis of POTS in the clinical
environment. Second, the meta-analysis will enable a summarization of current advice
from researchers that will be useful for the final proposal on reducing POTS misdiagnosis
rates. Ideas from Part One and Part Two will be synthesized into a final recommendation
for POTS education and diagnostic procedures. Such a two-pronged approach in reducing
the misdiagnosis rate for POTS is recommended based on evidence that suggests there is
not one “magic bullet” in approaching diagnostic error; thus, a multifaceted approach is
required not only in the clinic, but in this thesis as well.79
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Chapter Four: Examination of Other Frequently Misdiagnosed Conditions

Overview

The following chapter examines other frequently misdiagnosed conditions in an
attempt to learn how physicians approach and combat high rates of diagnostic error.
Information gained from an understanding of these maladies can then be applied to
reducing the rate of misdiagnosis for POTS. The following conditions were selected due to
their high rates of misdiagnosis and their assorted similarities to POTS. Before
investigating individual diseases and syndromes, approaches to reduce diagnostic rates in
general are discussed.

Literature Review

General Approaches to Reducing Diagnostic Error
Diagnostic errors are common not only for patients with POTS and the other
conditions discussed below, but in everyday medical practice. The World Health
Organization currently considers diagnostic error a high priority problem, and research on
the subject seems to support this claim.79 Rush et al. cite diagnostic errors as the “most
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common, costly, and dangerous of all medical mistakes.”73 A survey of over six thousand
doctors found at least 47% report diagnostic error occurring in their practice weekly; of
these, 40% of mistakes were due to flawed or inaccurate history taking.73 While one could
argue some diagnostic error is expected in the demanding and complicated field of
medicine, 96% of the surveyed physicians believed the diagnostic error they had reported
could have been prevented.73
Various approaches have been recommended for reducing overall rates of
diagnostic error. Singh et al. propose a lack of feedback contributes to the problem, as
doctors rarely learn they have provided a misdiagnosis. This communication breakdown
leads to inflated confidence in physicians’ diagnostic accuracy and denies doctors the
chance to learn from their mistakes.79 While an actual feedback mechanism to provide
doctors with performance results needs to be established, in the meantime, POTS patients
or their new physicians can reach out to previous doctors that have supplied inaccurate
diagnoses. No change in diagnostic error can be expected if the physicians diagnosing POTS
patients with psychiatric conditions, viral or bacterial infections, and/or other neurological
or cardiovascular disorders are alerted to their prior errors.
As mentioned previously, history-taking is a critical aspect of the diagnostic process,
and one wherein diagnostic error is likely to occur. One reason for this could be
communication difficulties – studies show patients are only able to speak to a physician for
an average of 18 seconds before being interrupted.73 Both doctors and POTS patients must
work together to ensure all aspects of a history are being communicated fully and clearly.
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Rush et al. propose the use of the pneumonic CARE to reduce the likelihood of
diagnostic errors:

Table 2: CARE Method

Communicate with your team and patient
Assess for Biased Reasoning
Reconsider Differential Diagnosis
Enact a Plan

When assessing for biased reasoning, Rush suggests considering questions such as
whether a colleague or patient first suggested the diagnosis, whether or not the patient is
being stereotyped, whether causes other than the obvious have been considered, and
whether the patient is perceived as having a “difficult” or “VIP” status. When reconsidering
differential diagnosis, Rush suggests a “time out” be taken to examine medical findings
inconsistent with the proposed diagnosis and ponder other possibilities.73

Hypothyroidism

Hypothyroidism, characterized by a decreased output of thyroid hormone (TH) or
decreased ability to utilize TH in the body, is a common but often misdiagnosed condition.
Reductions in thyroid function of as little as 15% can lead to symptoms of hypothyroidism,
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impacting as many as 33% of adults by current estimates, though not all cases are severe
enough to require treatment.23 Complicating matters further, the severity of symptoms
may not correlate appropriately with the severity thyroid dysfunction.90 As TH has
implications for almost every organ system symptoms are widespread and varied.90 This
diversity in clinical presentation likely contributes to poor rates of diagnosis: weight gain,
headache, fatigue, temperature sensitivity, depression, hair loss, vertigo, and constipation
are all indicative of low TH.23 Similar to POTS, hypothyroidism is more often seen in female
patients; the thyroid is five times more likely to be dysfunctional in women.23
Another symptom of hypothyroidism, decreased body temperature as a result of
decreased metabolic rate, provides the basis for a useful diagnostic procedure.23 Daily
axillary temperature recordings represent an easy and inexpensive test that has been
“ignored and derided by authorities” according to Durrant.23 Durrant et al. argue 90% of
hypothyroidism cases are missed due to an overreliance on serum lab results and
underappreciation of clearly presented symptoms. Lab results for T3, T4, and TSH fall into
broad ranges and are easily misconstrued by blood volume and renal clearance rate;
additionally, they fail to demonstrate receptor defects.23 These factors contribute to
Durrant’s argument that hypothyroidism misdiagnosis is exacerbated by poor clinical
evaluation of history and symptoms and a dependency on lab tests that are often flawed.
Most noticeable in this discussion of hypothyroidism diagnosis is the fear that simple yet
effective tests have been ignored, representing a potential similarity to POTS. The future
research portion of thesis will examine whether or not a heart rate/blood pressure
screening test could be such an overlooked option for POTS.

21

In the elderly, symptoms of hypothyroidism such as muscle weakness, bradycardia,
temperature intolerance, and decreased renal function may be overlooked or dismissed as
normal signs of aging.55 Due to these subtle symptoms, Maselli et al. propose routine TSH
testing in older adults could be justified. The masking of hypothyroidism in elderly patients
could be similar to the masking of POTS in older teen/young adult patients. Symptoms such
as fatigue, “brain fog,” and not feeling refreshed after sleep may be misinterpreted as signs
of depression, a more common disorder impacting patients of this age.
Congenital hypothyroidism is common as well, but less frequently misdiagnosed.
Neonatal screening catches most cases of congenital hypothyroidism, and stricter
screening methods following a lowering of the TSH threshold required for a diagnosis has
led to even the mildest cases being discovered.90 This screening is essential, as areas
lacking such measures are yet characterized by high rates of congenital hypothyroidismcaused intellectual disability.90 Such examples demonstrate the importance of screening
methods for frequently misdiagnosed conditions, supporting the argument of a heart
rate/blood pressure screening method for POTS. The improvements seen after adjusting
TSH threshold levels calls into question whether other frequently misdiagnosed conditions
could benefit from reevaluations of threshold levels; for example, the 30 bpm increase in
heart rate considered to be indicative of POTS.
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Fibromyalgia

Fibromyalgia (FM) is a rheumatic condition characterized by widespread pain and
sensitivity to pressure points. Although an understood and fairly common rheumatic
condition, second in prevalence only to osteoarthritis, misdiagnosis and an extended
period of time before accurate diagnosis is frequently seen in FM patients.22 Similarities to
other conditions complicate diagnosis; FM is often misdiagnosed as arthritis, connective
tissue disease, and spondyloarthropathies.22 Diagnosis can also be confused with
myofascial pain syndrome, chronic fatigue syndrome, and depression; furthermore, FM was
found to be the true disease state in many patients first diagnosed with Lyme disease.57 An
understanding of the incidence of FM has changed over time – once thought to be a rare
condition, current studies estimate 2-3% or even as high as 5% of the population are
affected.22, 57 Increased physician awareness led to more frequent and more accurate
diagnosis, calling into question whether other frequently misdiagnosed conditions, such as
POTS, will have a higher incidence once better understood. Ming et al. propose physicians
should continue to become more knowledgeable about FM and keep the condition in mind
when examining patients whose history seems indicative of FM, a suggestion that could
benefit POTS patients as well.57
FM was selected for study due to various similarities to POTS in addition to the high
rates of misdiagnosis. FM is diagnosed ten times more often in women,26 meaning over
90% of FM patients are female.22 This parallels the higher incidence of POTS seen in
women. Additionally, as in POTS, FM is a chronic and multi-systemic condition, leading to
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varied symptoms.22 Fatigue, Raynaud’s, sleep disturbances, irritable bowel syndrome,
depression, and anxiety are all considered FM symptoms.22 The most common symptom,
widespread pain, is considered vague and non-specific,22 mirroring the generalized feeling
of malaise seen in POTS and likely contributing to diagnostic error in both conditions.
Another similarity to POTS is the availability of clearly defined diagnostic criteria
that is ignored by clinicians. Just as POTS should be diagnosed based on increase in HR of
30 pm upon standing, FM should be diagnosed in patients with widespread pain and
tenderness at 11 out of 18 specific tender points (TP), as decided by the American College
of Rheumatology.22, 57 Ming et al. propose physicians learn to be comfortable making a
diagnosis of FM based only on a history and TP criteria, as other clinical measures are
flawed and contribute to high rates of diagnostic error.57
Work being done to combat the high rates of misdiagnosis in FM includes that of
Fitzcharles et al., who have identified a clear deficiency in understanding of FM diagnosis
among physicians. After following a rheumatology clinic over a period of six months, they
determined only 34% of patients referred to the clinic for FM were indeed FM patients;
additionally, 17% of those referred to the clinic for conditions other than FM turned out to
be actual FM patients.26 Such findings have been replicated; Calabozo et al. following a
rheumatology clinic over the course of a year and found 10% of those referred under other
syndromes were actually FM sufferers.10 These statistics demonstrate a general deficit in
physician understanding and ability to differentiate FM from other rheumatic conditions.
To combat this, Fitzcharles et al. utilized their research to identify characteristics that
should have been indicative of FM in these misdiagnosed patients, citing more fatigue, less

24

early morning stiffness, and reduction in spinal mobility deficits as tools for selecting FM
over other rheumatic diagnoses.26 Related to this problem is the work of DiFranco et al.,
who argue one problem for FM diagnosis is the absence of a “gold standard;” no laboratory
tests are considered hallmarks for the condition, yet various non-specific lab results
seemed to deter physicians from diagnosing FM.22 Again, as Ming et al. cited, clinicians
seem to ignore the easily available TP screening.57 The work of Fitzcharles et al.
demonstrated the potential for such a tool, as their study identified those with FM to have
an average of 12.5 TPs, while those without FM averaged only 4 TPs.26 DiFranco et al. agree,
suggesting physicians begin to utilize the TP assessment and consider FM when patient
symptoms appear vague and diverse.22

Lyme Disease

Lyme disease is caused by the spirochete Borrelia burgdorferi, usually transmitted
by the deer tick Ixodes scapularis. The infectious disease is characterized by fever, chills,
malaise, fatigue, generalized achiness, and head and neck pain.3, 58 Advanced cases can
progress to include carditis, arthritis, and central nervous system deficits.58 Overall, the
symptoms of Lyme disease collectively yield a clinical presentation similar to that of many
non-specific viral illnesses, complicating diagnosis, as will be discussed.3 Thus, similar to
POTS, the condition features generalized and diffuse symptoms. Successful antimicrobial
therapy exists for those diagnosed with Lyme disease, meaning for many patients,
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continued problematic symptoms are more likely to be due to misdiagnosis than failure of
treatment.58
Despite its commonality in the US – Lyme disease is the most common vector-borne
illness – the condition has continued to be frequently misdiagnosed.3, 58 Estimates suggest
the disease could be as much as 12 times more prevalent than is reported.3 Complicating
diagnosis is the potential for overlap between peak tick season and viral outbreaks.3
Misunderstanding about the presentation of Lyme disease also exists among physicians.
The commonly expected “bulls-eye” appearance of the hallmark erythema migrans rash is
only present in a minority of patients. Most often, a rash will appear uniform; additionally,
in up to 16% of patients, a rash will be entirely absent.3, 58
Interestingly, physicians also demonstrate a tendency to over-diagnose Lyme
disease, again based on misunderstanding about the condition.6, 58 Physicians readily
perform serological testing in patients with only a few symptoms – malaise, fatigue, etc. –
that could be indicative of a number of disorders.6, 58 Such testing could lead to
misdiagnosis and/or over-diagnosis, as both false positives and false negatives are frequent
occurrences.3 Serological testing currently involves a two-step procedure in which a
positive ELISA is followed by a Western blot. However, research shows such tests are
unable to distinguish between a previous infection and an active infection, and thus have
limited utility.6
Recommendations for combatting misdiagnosis include considering the isolated
geographic origins of the disease when examining patients – most cases occur in
northeastern states, meaning those who live in or travel to these areas are far more likely
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to have Lyme disease.3 Physicians should also be aware of biases that could be priming
their decision-making processes; for example, media coverage of viral outbreaks.3 No gold
standard exists for Lyme disease diagnostic testing, and automatic Western blotting may
not be recommended even in the case of a positive ELISA.6 Instead, all researchers stress
the importance of thorough history and physical exams in the accurate diagnosis of Lyme
disease.3, 6, 58

Lupus
Lupus (systemic lupus erythematosus, SLE) is a chronic autoimmune disease
causing widespread inflammation affecting multiple organ systems.45 The skin, joints,
kidneys, blood, and nervous system are primarily affected.24 Symptoms include pain,
swelling, stiff joints, and fatigue, fever, and rash.24, 45 Lupus affects mostly women; current
estimates suggest 10-12 times more females than males are afflicted.24, 45 The condition is
also observed more frequently in black women than white women.24 Thus, as in
hypothyroidism, fibromyalgia, and POTS, women are predominantly affected.
Additionally, as seen in POTS and a number of the other conditions analyzed, the
generalized nature of the symptoms contributes to difficulty in diagnosing the disease.45, 89
Over 70% of lupus patients are initially misdiagnosed, causing most patients to wait years
for an accurate diagnosis. 45, 89 A survey conducted among lupus patients and caretakers
revealed lupus patients visited a median three physicians over the course of a median ten
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appointments before receiving a correct lupus diagnosis.45 Rheumatoid arthritis
represented the most common incorrect diagnosis; like POTS, many lupus patients were
also initially misdiagnosed with a mental health disorder such as depression.45 Research
shows this misdiagnosis is not only physically dangerous, but psychologically and
economically burdensome.89
Recommendations to reduce the high rate of misdiagnosis seen in lupus highlight
increasing awareness and education among medical providers.24, 45, 89 The triad of fever,
rash, and joint pain should be considered particularly indicative of lupus.24 Proper history
taking and physicals are also emphasized.24 Additionally, surveys suggest physicians may
dismiss non-specific and seemingly minor symptoms that, when considered as a whole,
significantly affect patient wellbeing. Oversights such as these contribute to high rates of
misdiagnoses and diminished patient quality of life.89

Common Themes

The major conclusions from the examinations of other frequently misdiagnosed
conditions are outlined below; overall, analysis suggests the underlying cause(s) for
misdiagnosis are similar across conditions. Diffuse, varied, and multisystemic symptoms
(POTS, hypothyroidism, fibromyalgia, Lyme disease, lupus) was a characteristic of all
analyzed pathologies, and likely represents the most significant source of diagnostic error.
Additionally, a higher prevalence in females was a common trait (POTS, hypothyroidism,
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fibromyalgia, lupus). Many arguments from the literature demonstrate a belief that
physicians should be able to discern these frequently misdiagnosed conditions from clinical
examinations and histories (hypothyroidism, fibromyalgia, Lyme disease, lupus); reliance
on more extensive and expensive laboratory testing is problematic. In both hypothyroidism
and fibromyalgia, physicians distrust what should be hallmark features of the condition in
favor of lab tests (temperature recordings in hypothyroidism and tender points in
fibromyalgia syndrome). The idea that a heart rate increase based on an in-clinic screening
should be used as such a hallmark feature in POTS is the basis for research presented as
future implications later on.
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Table 3: Summary of Examination of Misdiagnosed Conditions

Misdiagnosed
Condition

General
diagnostic error

Hypothyroidism

Fibromyalgia

Lyme Disease

Lupus

Similarities to POTS

(Not applicable)

Clinical Suggestions


Take a thorough history



Improve feedback



Utilize CARE



Consider bias



Consider alternatives



Employ routine screening



Consider easy/cheap tests



Adjust screening thresholds



Multisystemic symptoms



More common in females



Age may skew interpretation



Easy tests are ignored



Multisystemic symptoms



Prevalence may be higher



More common in females



Define hallmark features



Easy tests are ignored



Increase clinician awareness



Multisystemic symptoms



Blood tests are misleading



Focus on history, physical



Diagnostic tests are lacking



Consider patient population



Misunderstanding exists



Avoid bias



Multisystemic symptoms



Focus on history, physical



More common in females



Increase physician awareness



Misunderstanding exists



Define hallmark features
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Chapter Five: Meta-Analysis on POTS

Methodology

The following meta-analysis on recent research done on POTS was conducted
through a systematic review of available literature on PubMed. Studies were isolated
through a search for articles containing both the phrases “postural orthostatic tachycardia
syndrome” and “clinical study.” This search produced 58 results. While additional focused
selection criteria may be necessary for other meta-analyses, the relatively small number of
current studies performed on POTS permits a review of all the literature. One study was
removed due to language barriers, as the study was written in Chinese. Four other studies
were removed after it was determined they did not perform primary research on POTS:
one as the research focused on vasovagal syncope patients mimicking POTS, not POTS
itself; one for its focus on orthostatic hypotension rather than POTS; and two wherein POTS
became a side effect experienced by those in the study rather than the investigated
condition. Thus, a total of 53 studies were selected to be reviewed.
As will be discussed below, analysis of the selected articles led to the conclusion that
most research on POTS refers to the syndrome as “postural tachycardia syndrome” rather
than “postural orthostatic tachycardia syndrome.” In order to ensure a significant number
of studies on POTS were not missed, the process described above was repeated with the
search terms “postural tachycardia syndrome” and “clinical study.” This search produced
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50 results, 5 of which were articles not selected by the previous method. One of these
studies was removed for its focus on postmenopausal symptoms rather than POTS. The
remaining four were included in the meta-analysis leading to a total of 57 studies.
Finally, the selection of articles on PubMed was double-checked through the use of
the site’s filters. A search for “postural orthostatic tachycardia syndrome” yields 507
results; after selecting the article-type filter “clinical trial” the results are narrowed to 45,
all of which were selected with the previously described methodology. A search for the
variation “postural tachycardia syndrome” yields 370 results; after selecting the filter
“clinical trial” the results are narrowed to 50, all of which were selected with the previously
described methodology.

Results

See appendix for a table detailing each study. Studies are listed by article title, and
described underneath by the topic or objective of the study, sample size, and conclusion.
Studies are listed in the order they were reviewed, i.e. by PubMed’s judgement of their
relevance.
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Preliminary Data

A number of ideas can be extracted from the meta-analysis before even addressing
the individual research studies. The figures below demonstrate the number of publications
referencing POTS (through a search of “postural orthostatic tachycardia syndrome” OR
“postural tachycardia syndrome”) by year (see Figure 1), as well as the number of clinical
studies performed on POTS by year (i.e. those analyzed in the meta-analysis) (see Figure
2).
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Figure 1: PubMed Review: References to POTS by Year
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Figure 2: PubMed Meta-Analysis: POTS Clinical Studies by Year

Additionally, analyzing the titles and abstracts of the studies selected for metaanalysis shows there are variations in the terminology researchers use to describe POTS.
As depicted in the diagram below (see Figure 3), most studies refer to POTS as “postural
tachycardia syndrome” (37 out of 57 studies). Some studies refer to POTS as “postural
orthostatic tachycardia syndrome” (17 out of 57 studies). One study refers to POTS as
“orthostatic tachycardia syndrome” (1 out of 57 studies). Despite these variations, all of the
above studies utilized the acronym “POTS.” Two studies, however, differed in their use of
“PoTS” rather than “POTS” (2 out of 57 studies).
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Orthostatic
Tachycardia
Syndrome

PoTS

Postural Orthostatic
Tachycardia
Syndrome

Postural
Tachycardia
Syndrome

Figure 3: Terminology Used for POTS

Finally, analyzing the impact factors of the journals in which the analyzed studies
were published can provide an understanding of how successful clinical studies on POTS
have been at disseminating their conclusions (see Table 4). The range of impact factors was
0.190 – 19.896, with an average impact factor of 5.13 and a median impact factor of 3.243.
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Table 4: Meta-Analysis Impact Factors

Journal

AJP Heart and Circulatory Physiology
AJP Regulatory, Integrative & Comparative
Physiology
Annals of Pharmacotherapy
Cardiology in the Young
Cardiovascular Therapeutics
The Central European Journal of Medicine
Chinese Journal of Pediatrics
Circulation
Circulation: Arrhythmia and Electrophysiology
Circulation Journal
Clinical Autonomic Research
Clinical and Experimental Pharmacology and
Physiology
Clinical Science (London)
European Journal of Neurology
European Neurology
Experimental Brain Research
Frontiers in Neuroscience
Heart Rhythm
Hypertension
Journal of Applied Physiology
Journal of the American College of Cardiology
Journal of the American Heart Association
Journal of the Autonomic Nervous System
Journal of Clinical Psychopharmacology
Journal of Interventional Cardiac
Electrophysiology
Journal of the Kentucky Medical Association
Journal of Pediatrics
Journal of Physiology
Journal of Psychopharmacology
Medical Science Monitor
Medicine (Baltimore)
Neurogastroenterology & Motility
Neurology
Pacing and Clinical Electrophysiology
PLoS One
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Number
3

Impact Factor
3.348

1

2.982

1
1
1
1
3
6
2
1
6

2.059
0.905
2.478
0.974
0.190
19.309
6.462
4.124
1.276

1

2.010

1
1
1
1
2
2
2
2
1
1
3
1
1

4.936
3.956
1.697
2.395
3.566
5.076
6.857
3.056
19.896
5.117
3.240
3.243
1.826

1
1
1
1
1
1
1
2
1
1

0.290
3.890
4.739
3.593
1.433
1.630
3.617
8.320
1.486
2.806

Meta-Analysis

Below, a breakdown of the different types of research identified through the metaanalysis is shown (see Table 5). Research was subdivided into five categories: research on
the prevalence of POTS, the etiology and/or characteristics of the condition, diagnostic
procedures used to identify POTS, case reports on POTS patients, and treatment. Treatment
can be subdivided into non-pharmacological and pharmacological intervention (see Tables
6 and 7).

Table 5: Categories of Clinical Studies

Type of Research
Prevalence of POTS
Etiology/Characterization of POTS
Diagnostic Procedures
Case Reports
Treatment

Number of
Clinical Studies
2
18
2
3
35

Table 6: Categories of Non-Pharmacologic Treatment

Type of Non-Pharmacologic Treatment
Acute Fluid Ingestion
Exercise Training
HIRREM
Inspiratory Resistance
Saline Injections
Sleep Treatment
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Number of
Clinical Studies
1
3
1
1
1
1

Table 7: Categories of Pharmacologic Treatment

Type of Pharmacologic Treatment
Ang II Receptor Blocker
Ascorbate
Beta-Blockers
Bisoprolol
Desmopressin
Esmolol
Fludrocortisone
Melatonin
Metoprolol
Midodrine Hydrochloride
Modafinil
NRI
Octreotide
Phenylepinephrine
Propranolol
Pyridostigmine
SSRI

Number of
Clinical Studies
1
1
1
1
1
1
1
1
3
7
1
1
1
1
3
2
1

Discussion

Discussion of Preliminary Data
A look at the increase in the number of studies referencing POTS over time (Figure
1) shows a strong positive trend since its official clinical description in 1993, suggesting the
medical field is on the right track in terms of increasing awareness of the condition.
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Comparing this pattern to that of the increase in clinical studies on POTS over time (Figure
2) unfortunately seems to suggest the rate of current research on POTS is not keeping up
with the apparent surge in awareness of the condition. Very few clinical studies on POTS
are produced every year, and many of those that are published originate from the same
research group. Finally, as will be discussed later, the studies that are available are failing
to address the most important issues.
The variation in terminology used to describe POTS is also problematic. Despite the
fact that the acronym POTS definitively stands for “postural orthostatic tachycardia
syndrome,” only about 30% of studies refer to it as such. The most common phrase,
“postural tachycardia syndrome,” was used in 65% of studies. While only differing by one
word, the removal of the term “orthostatic” could drastically alter understanding of the
condition, especially considering an orthostatic heart rate/blood pressure test defines the
syndrome and could represent a potential screening method for patients. Other terms used,
such as “orthostatic tachycardia syndrome” and “PoTS” (implying the acronym stands for
only postural tachycardia syndrome, again leaving out the important orthostatic), further
complicate the literature. Such differences in phrasing could be unimportant for a more
familiar condition, but may be significant in this instance. Considering POTS is already an
under-recognized syndrome that many physicians may lack experience with, frequent
changes in the terminology will only serve to exacerbate confusion in the medical field.
The typical impact factors of the journals publishing clinical studies on POTS are
average; rankings above 3 are considered to be in the top 20% of journals according to the
Journal Citations Report, meaning 34 of the 57 studies analyzed are in such top-tier
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journals. While publishing in more frequently cited journals would not be detrimental, the
quality of the journals disseminating information on POTS is likely not the most significant
problem facing POTS education.

Discussion of Meta-Analysis

Examining the number of clinical studies published in each of the identified
categories (prevalence, etiology/characteristics, diagnostic procedures, case reports, and
treatment) shows most current research on POTS is aimed at isolating a cause for POTS
and testing pharmacologic intervention, themes that are questionable in terms of their
ability to actually change the way POTS is handled in the medical field. As demonstrated by
the initial literature review, many causes for POTS have already been identified and
characterized. However, it seems most physicians proceed with a similar set of therapies
regardless of a patient’s underlying etiology. Additionally, the side effects from these
treatments can be difficult for the patient to tolerate, leading to the use of over-the counter
therapies such as salt tablets, oral rehydration, compression stockings, and exercise
training. Thus, characterizing the etiology for POTS (as 32% of studies did) and analyzing
treatment options (as 61% of studies did) has limited utility.
Instead, as it seems the most important aspect to recovering from POTS is simply
receiving a POTS diagnosis, thus, the types of clinical studies that could have the greatest
impact on the rate of misdiagnosis for POTS would be those aimed at developing a more
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accurate understanding of the prevalence of the condition (as only 3.5% of studies did) and
rethinking diagnostic procedures (again, as only 3.5% of studies did). Most researchers
believe the incidence of POTS is greatly underestimated, meaning more comprehensive
studies designed to identify POTS patients could lead to higher estimates of its prevalence.
A more accurate knowledge of the incidence of POTS could then lead to increased physician
awareness, more research studies, and overall reduced rates of misdiagnosis for patients.
Similarly, rethinking the diagnostic process to identify patients sooner reduce such rates.
The four studies that did approach prevalence and/or diagnostic procedures show
promise that future work in this area could yield positive results. For example, one trial
found 9.5% of patients with multiple sclerosis (MS) to have POTS; if the study can be
assumed to apply to the population at large, such a statistic could mean tens of thousands
of MS patients in the United States have undiagnosed POTS. Another found 32.2% of child
syncope cases in China to be due to POTS, again suggesting prevalence could be much
higher than initial studies suggest. Studies on diagnostic procedures suggest a history of
syncope associated with heart palpitations, dizziness, and headaches is more important for
making a POTS diagnosis than a tilt table test, and that that Schellong test could replace the
tilt table test with up to 61% specificity.
Finally, although this thesis is targeted at reducing the rate of misdiagnosis for POTS
rather than recommending a course of treatment for POTS, a brief look at the performed
clinical studies (see Table 5) demonstrates a clear need for a comprehensive study aimed
at determining the most effective routes for therapy. With six types of non-pharmacologic
and seventeen types of pharmacologic therapy – not to mention the fact that some
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therapies could be utilized simultaneously – there are simply too many possibilities for a
physician to consider. Even when the analyzed studies compared therapies, only two or
three of the twenty-three avenues for treatment were used. A more definitive and
standardized method to treat POTS would benefit patients and help physicians not feel
overwhelmed by an already confusing condition. Perhaps a flow chart mapping out therapy
options could be developed.
Within the aforementioned therapies, five were studied by more than one research
group, leading to the need for a meta-analysis of their conclusions. Three studies analyzed
the efficacy of exercise training in the treatment of POTS; all found exercise training to be
beneficial in reducing symptoms and improving cardiovascular function. Three studies
analyzed the use of metoprolol in treating POTS; all found metoprolol reduced symptoms,
though one study found it was not as effective at mitigating symptoms as midodrine
hydrochloride. Seven studies analyzed the use of midodrine hydrochloride in treating
POTS, which seems to be the most common therapy utilized; all found midodrine
hydrochloride to be a beneficial therapy, except in the specific case of hyperadrenergic
POTS. Midodrine was found to be more effective than metoprolol, salt therapy, and
octreotide, but less effective than beta-blockers. Midodrine plus salt therapy was the most
effective therapy. Three studies analyzed the use of propranolol in treating POTS; all found
propranolol to be beneficial, but only at low doses; additionally, exercise therapy was found
to be superior. Two studies analyzed the use of pyridostigmine in treating POTS; one found
pyridostigmine to reduce tachycardia, while the other did not. Further research on the
utility of pyridostigmine could be useful.
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Chapter Six: Future Research
As has been alluded to throughout this thesis, reduction in misdiagnoses of POTS
patients is doubtful without widespread implementation of an easier method to identify
POTS candidates. While not ideal, the use of a simple supine to standing heart rate and
blood pressure screening at the primary care level is the most apparent solution. A report
of extended excessive fatigue not alleviated by rest, in addition to lightheadedness and presyncope symptoms, should be considered indicators for a potential POTS diagnosis in
females of childbearing age. A history of syncope, palpitations, dyspnea, numbness, and/or
exercise and heat intolerance should indicate that a mechanism other than anxiety or
depression is to blame. Once a health care provider has ruled out ailments such as bacterial
and viral infections, a simple ten-minute screening mimicking a tilt table test should be
used to consider POTS in such patients. This can be accomplished by asking patients to lie
in a supine position for five to ten minutes while monitoring heart and blood pressure, and
comparing vital signs after transitioning to a standing position. An increase in heart rate of
at least 30 bpm in adults or 40 bpm in teenagers indicates POTS should be considered.
Future research should implement a study of this method on able volunteers in the
general population to determine the usefulness of this technique. Demonstrating that the
vast majority of non-POTS individuals fail to show a 30 bpm increase in heart rate upon
standing would indicate that implementation of this procedure on a wider scale would not
unnecessarily identify large numbers of patients for unneeded further testing, and instead
flag only those in whom POTS is a real concern. Such a screening would proceed as follows:
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Materials: Blood pressure cuff, timer, mat
1. Identify able and willing volunteer
2. Ask volunteer to fill out anonymous form identifying age, gender, and presence
of POTS related symptoms
3. Ask volunteer to lie on mat in a supine position in a quiet environment; take
heart rate/blood pressure after 5 minutes
4. Ask volunteer to stand; take heart rate/blood pressure immediately and after 2
minutes of standing
5. Record heart rate/blood pressure on aforementioned form
Volunteers who do demonstrate an increase in heart rate of 30 bpm upon standing
would be assured that this test does not represent an accurate medical diagnosis.
Information about POTS will be available for those interested. See Appendix B for an
example of the form to be utilized. Such a research project could be completed in either a
clinical or non-clinical environment.
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Chapter Seven: Conclusion
An examination of POTS shows that changes can be made in the medical community
to reduce the high rates of misdiagnosis surrounding the condition. Although a “gold
standard” for POTS diagnosis exists in the form of the tilt-table-test, its expense diminishes
its utility in identifying many patients. Thus, changes to clinical practice that can be
implemented with minimal time and cost are more likely to reduce misdiagnosis rates and
identify POTS patients sooner. Research on other frequently misdiagnosed conditions and a
meta-analysis on current POTS research has led to the following proposals for improving
POTS diagnosis.
Analysis demonstrates the aspects of POTS that most likely contribute to its
misdiagnosis are its generalized symptoms, prevalence in young women, lack of
appropriate diagnostic procedures, and the confusion about the condition within the
medical community. Obviously, its presentation and epidemiology cannot be changed;
however, diagnostic procedures and misunderstanding among medical professionals can
be addressed.
History taking represents a critical part of the diagnosis of POTS and other
commonly misdiagnosed conditions. Physicians should ensure POTS is considered in a
differential diagnosis for patients presenting with fatigue, weakness, dizziness, presyncope, and other POTS symptoms. While discussing patient history with such individuals,
doctors should ask questions such as “Are your symptoms worse upon standing?” and
“When you felt faint (or fainted), what were you doing?” to isolate the underlying cause of
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syncope. Orthostatic dizziness or fainting should indicate POTS is a possible diagnosis.
Doctors should refrain from frequently interrupting patients during a history, and patients
should ensure all aspects of symptoms or syncopal episodes are discussed. Physicians can
utilize the aforementioned “CARE” method when working with patients whose diagnoses
are not immediately apparent, making sure biased reasoning is not impacting decisionmaking – for example, assuming a teenaged patient is depressed or accepting the
recommendation of another physician. The fact that many misdiagnosed conditions are
most often seen in women suggests possible gender biases should be considered and
adjusted as well. Finally, the medical community at large must consider the potential
benefits in implementing feedback systems that allow doctors to learn from their mistakes.
Analysis of other frequently misdiagnosed conditions demonstrates many such
ailments are characterized by easy in-clinic assessments that could be used to diagnose
patients; however, physicians seem to distrust such measures, and instead rely on often
inaccurate laboratory testing. POTS should be considered one of the conditions wherein
this flawed system is at work. The clinical definition of POTS - an increase in heart rate of
30 bpm or more upon standing - represents what could be an overlooked, inexpensive, and
easy method to identify POTS patients in clinics. Patients who present as likely POTS
candidates based on age, gender, and symptomology should be asked to complete a simple
heart rate/blood pressure test while seated and while standing in order to rule out POTS.
A standardized screening utilizing such a heart rate/blood pressure test could easily
identify POTS patients with minimal time and effort in the appropriate settings; family
medicine, cardiovascular, and neurological clinics should consider implementing a standing
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heart rate/blood pressure test in addition to a seated assessment. Such a screening would
not represent an extra cost to physicians or hospitals, and could be completed while
patients await the doctor during an appointment. The heart rate/blood pressure screening
test would not only identify POTS patients, but also those with orthostatic hypotension and
other forms of dysautonomia. Future research should determine the utility of such a
screening test in the clinical setting.
Current research on POTS unfortunately fails to address the aspects of the condition
that contribute to misdiagnosis. Meta-analysis shows most current research on POTS
focuses on the etiology of the condition (32%) or pharmacological therapy (47%). A
holistic review of POTS, however, shows these efforts are misguided. Although research on
the etiology of the disease has helped to characterize the condition, such information does
not play a role in patient diagnosis and patient quality of life, as it is highly unlikely that
patients outside of a hospitalized clinical study will undergo testing to determine which
subtype of POTS (hypovolemic, neuropathic, hyperadrenergic, etc.) best explains their
symptoms. Thus, focused research on pharmacological therapy targeted to such subtypes
will likely not impact many patients – administration of medication seems to more usually
follow a trial-and-error process. Few POTS researchers are approaching the condition with
an interest in diagnostic procedures (3.5%). This deficit must be corrected, as simply
reaching an accurate POTS diagnosis is often the turning point for dysautonomia patients –
studies show accurate diagnosis and subsequent therapy leads to improvement in 80% of
patients, with 60% reaching a near-normal quality of life.76 Most therapies that mitigate
POTS symptoms are over-the-counter or non-pharmacological (salt tablets, supplements,
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fluid ingestion, exercise therapy). For those patients that do try pharmacological therapy,
many treatment options are available and have been well characterized. Thus, the most
difficult, yet arguably most significant, aspect of treating a POTS patient is simply
identifying the correct condition (POTS) and providing patient education.
Before physicians can provide patient education, however, misunderstandings
about POTS within the medical community must be addressed. The general increase in
both POTS clinical studies and articles referencing POTS since its clinical description in
1993 suggests awareness is increasing; however, when compared to other conditions, the
amount of research being performed on POTS is still minimal. Additionally,
misunderstanding may increase while awareness increases due to the variation in
terminology used to refer to POTS. Only 30% of studies utilize the term “postural
orthostatic tachycardia syndrome,” instead referring to the syndrome as “postural
tachycardia syndrome” or “orthostatic tachycardia syndrome.” Finally, the fact that POTS
was not defined until 1993 presents the possibility for generations of practicing physicians
unaware of the condition at all.
In conclusion, despite the difficulties surrounding POTS diagnosis, slight changes to
clinical practice could dramatically reduce the high rates of misdiagnosis. Quicker detection
and accurate diagnosis would improve the health-related quality of life of many POTS
patients unaware of their condition. Physicians should consider the aforementioned
recommendations on history-taking and heart rate/blood pressure screenings, while
researchers studying POTS should focus on streamlining diagnostic procedures.
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Table 8: Meta-Analysis Summary

Study Title
Source
Number
62

Topic

Conclusions

Understanding the placebo effect in clinical trials for postural orthostatic
tachycardia syndrome
Placebo on tachycardia

39

Sample
Size

Decrease in tachycardia over time is due
to physiological changes, not a placebo

21

Melatonin reduces tachycardia in postural tachycardia syndrome (POTS): a
randomized, crossover trial
Melatonin on
tachycardia

Oral melatonin reduced orthostatic
tachycardia more so than placebo

78

Inspiratory resistance improves postural tachycardia: a randomized study
33

2

Inspiratory resistance
on orthostatic tolerance

Negative intrathoracic pressure improves
heart rate control

26

Low-dose propranolol and exercise capacity in postural tachycardia
syndrome: a randomized study
Propranolol on exercise
tolerance

Propranolol may benefit POTS patients
during exercise by improving SV and HR

18

Structural and functional small fiber abnormalities in the neuropathic postural
tachycardia syndrome
37

94

Identify neuropathic
from non-neuropathic
POTS patients

Nerve fiber density, quantitative sensory
testing, and autonomic testing can
distinguish neuropathic from nonneuropathic POTS

34

Midregional pro-adrenomedullin as a predictor for therapeutic response to
midodrine hydrochloride in children with postural orthostatic tachycardia
syndrome
MR-proADM on
predicting midodrine
hydrochloride reponse

MR-proADM can be used to predict
efficacy of midodrine hydrochloride

77

A clinical manifestation-based prediction of hemodynamic patterns of
orthostatic intolerance in children: a multi-center study
14

Necessity of tilt table
test in diagnosis

History of syncope associated with
palpitation, dizziness, headache was most
important for diagnosis

629

50

30

47

15

40

Exercise training versus propranolol in the treatment of the postural
orthostatic tachycardia syndrome
Exercise vs. propranolol
in treating POTS

Hemodynamic profiles and tolerability of modafinil in the treatment of
postural tachycardia syndrome: a randomized, placebo-controlled trial
Modafinil on cognitive,
tachycardia symptoms

59

Modafinil does not worsen tachycardia
and thus could treat cognitive symptoms

54

Midodrine hydrochloride is effective in the treatment of children with postural
orthostatic tachycardia syndrome
Midodrine vs.
metoprolol for POTS

Midodrine is more effective than
metoprolol and/or conventional therapy

53

Effects of norepinephrine reuptake inhibition on postural tachycardia
syndrome
NRI on POTS symptoms

54

Exercise training is more effective at
mitigating symptoms than propranolol

34

NRI drugs increase HR and worsen
symptoms in POTS

27

Acute hemodynamic effects of a selective serotonin reuptake inhibitor in
postural tachycardia syndrome: a randomized, crossover trial
SSRI on mitigating POTS
symptoms

SSRIs are not associated with reduced HR
or improved symptoms in POTS

39

Altered systemic hemodynamic and baroreflex response to angiotensin II in
postural tachycardia syndrome
Response to Ang II
infusion

POTS patients have impaired Ang II
response and baroreflex function

28

Desmopressin acutely decreases tachycardia and improves symptoms in the
postural tachycardia syndrome
17

Desmopressin on
treating POTS

Desmopressin reduces tachycardia and
other symptoms by increasing blood
volume

30

Outcomes in adolescents with postural orthostatic tachycardia syndrome
treated with midodrine and beta-blockers
48

Midodrine vs. betablockers for POTS

Midodrine and beta-blockers both
improved symptoms, but beta-blockers
are more associated with improvement

47

Ascorbate improves circulation in postural tachycardia syndrome
85

Ascorbate on low-flow
POTS patients

Ascorbate could mitigate POTS symptoms
but is excreted too rapidly

20

51

27

Use of an allostatic neurotechnology by adolescents with postural orthostatic
tachycardia syndrome (POTS) is associated with improvements in heart rate
variability and changes in temporal lobe electrical activity
Use of HIRREM for
brain oscillations

41

Reduced autonomic symptoms are seen
after use of HIRREM neurotechnology

7

Postural orthostatic tachycardia syndrome is associated with platelet storage
pool deficiency
Etiology of POTS;
platelet pool deficiency

Platelet pool deficiency is a frequent
comorbidity seen in POTS

181

Propranolol decreases tachycardia and improves symptoms in the postural
tachycardia syndrome: less is more
70

78

Propranolol on
tachycardia

Low dose propranolol mitigates
tachycardia and improves symptoms; high
dose may worsen symptoms

54

Short-term exercise training improves the cardiovascular response to exercise
in the postural orthostatic tachycardia syndrome
Circulatory control and
exercise conditioning

Short-term exercise training improves
cardiovascular response during exercise

19

Therapies for postural tachycardia syndrome in children
93

72

Oral rehydration salts,
metoprolol, midodrine
hydrochloride

A double-blind placebo-controlled cross-over study of the vascular effects of
midodrine in neuropathic compared with hyperadrenergic postural
tachycardia syndrome
Neuropathic vs.
Hyperadrenergic POTS

32

All therapies improve symptoms; most
effective is salts plus midodrine

118

Midodrine is effective in neuropathic, but
not hyperadrenergic, POTS

20

Nitric oxide and regulation of heart rate in patients with postural tachycardia
syndrome and healthy subjects
NO on cardiovascular
regulation

13

No evidence for NO dysfunction in POTS

The utility of Valsalva maneuver in the diagnosis of orthostatic disorders
63

92

Hemodynamic
responses in OI

Valsalva maneuver response can
differentiate types of OI

66

Acute fluid ingestion in the treatment of orthostatic intolerance – important
implications for daily practice
Water intake and OI

14

Water and clear soup improve POTS OI
52

9

Vascular responses to orthostatic stress in patients with postural tachycardia
syndrome (POTS), in patients with low orthostatic tolerance, and
asymptomatic controls
Cardiac response in
POTS vs. low OI

POTS may be associated with peripheral
neuropathy; problems are due to
tachycardia, not hypotension

49

Case reports and review of postural orthostatic tachycardia syndrome
11

Case reports

POTS likely more common than we know;
important to make correct diagnosis

2

Clinical improvement in patients with orthostatic intolerance after treatment
with bisoprolol and fludrocortisone
28

12

Bisoprolol and
fludrocortisone on
symptoms

POTS may be due to hyperadrenergic or
hypovolemic response; bisoprolol and
fludrocortisone mitigate symptoms

22

Effect of selective alpha 1 receptor agonist in the treatment of children with
postural orthostatic tachycardia syndrome
Midodrine on
symptoms

Use of midodrine hydrochloride is
significantly more effective than salt alone

55

Pyridostigmine in the treatment of orthostatic intolerance
31

36

Pyridostigmine and HR

The international POTS registry: Evaluating the efficacy of an exercise training
intervention in a community setting
Exercise therapy

83

52

Pyridostigmine bromide reduces standing
HR, but not more than placebo

106

Training is effective in treating POTS;
more research is needed long-term

103

Splanchnic hyperemia and hypervolemia during Valsalva maneuver in
postural tachycardia syndrome
Splanchnic blood flow
POTS vs. control

POTS blood flow changes may be related
to increase in splanchnic blood flow

27

Comparison of the postural tachycardia syndrome (POTS) with orthostatic
hypotension due to autonomic failure
Venous pooling

Arterial function is intact but venomotor
function impaired

37

Reflex vascular defects in the orthostatic tachycardia syndrome of adolescents
87

Venous pressure and
blood low

Subsets of POTS seem to exist:
high Pv/low flow, and low Pv/high flow

35

53

84

86

69

Clinical and physiological effects of an acute alpha 1 adrenergic agonist and a
beta 1 adrenergic antagonist in chronic orthostatic intolerance
Phenylephrine and
esmolol

Phenylephrine (alpha 1 agonist) improves
OI; esmolol (beta 1 antagonist) does not

14

Angiotensin II type I receptor blockade corrects cutaneous nitric oxide deficit
in postural tachycardia syndrome
Losartan on NO-dept.
vasodilation

Ang II type 1 receptor blockade via
losartan corrects NO-dept. vasodilation

27

Acetylcholinesterase inhibition improves tachycardia in postural tachycardia
syndrome
Pyridostigmine on
tachycardia

Pyridostigmine significantly reduces
tachycardia and relieves symptoms

17

Cerebral autoregulation is preserved in postural tachycardia syndrome
77

Cerebral autoregulation
POTS vs. control

Cerebral perfusion is not altered in most
POTS patients

44

Underlying diseases in syncope of children in China
16

75

Syncope etiology

Certain cardiovascular indices predict syncope in the postural tachycardia
syndrome
Syncope predictors

46

21

50

While increased HR is universal, TPR
response to TTT varies

43

Experimental induction of panic-like symptoms in patients with postural
tachycardia syndrome
Relationship POTS and
panic disorder

POTS symptoms are different and
distinguishable from panic disorder

22

Cerebrovascular mechanisms in neurocardiogenic syncope with and without
postural tachycardia syndrome
Syncope etiology in TTT

43

Of 888 children suffering from syncope in
China, 32.2% were found to have POTS

888

16

Cerebral autoregulation is not affected

Treatment of postural tachycardia syndrome: a comparison of octreotide and
midodrine
Octreotide and
midodrine on OI

Both octreotide and midodrine mitigate
tachycardia on standing; both is not better

15

Self-reported post-exertional fatigue in Gulf War veterans: roles of autonomic
testing
Autonomic dysfunction
in veterans

One veteran complaining of fatigue was
found to have POTS

28

54

Schellong test in orthostatic dysregulation: a comparison with tilt-table testing
91

Schellong test vs. TTT

Schellong test specificity only 61% that of
TTT, but can be first step to diagnosis

67

Diagnosis of tachycardia syndromes associated with orthostatic symptoms
7

POTS HR

POTS HR is not affected during Valsalva
maneuver or deep breathing

18

Postural tachycardia syndrome: time frequency mapping
61

38

Neuropathic POTS

POTS identified in 9.5% if MS patients;
could be useful for diagnosis

84

Effects of intermittent intravenous saline infusions in patients with
medication-refractory postural tachycardia syndrome
Saline injections

51

Reflux problems in JHS are more likely
when comorbid with POTS

30

Postural orthostatic tachycardia predicts early conversion to multiple sclerosis
after clinically isolated syndrome
POTS and MS

74

Venous pooling is due to arterial defects,
not increased venous compliance

26

Mechanisms underlying reflux symptoms and dysphagia in patients with joint
hypermobility syndrome, with and without postural tachycardia syndrome
GI problems

42

POTS patients have increased
norepinephrine release

99

Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not
venous compliance defects
Venous pooling

25

40

Cardiac sympathetic dysautonomia in chronic orthostatic intolerance
syndromes
Norepinephrine levels

82

Impaired Valsalva maneuver and distal
sudomotor dysfunction indicates
neuropathic POTS

IV saline significantly reduces symptoms
and improves quality of life

57

Salivary cortisol levels predict therapeutic response to a sleep-promoting
method in children with postural tachycardia syndrome
Sleep treatment
predicted by cortisol

Salivary cortisol levels at waking may
predict sleep-treatment utility

60

55

20

Possible relationship between chronic fatigue and postural tachycardia
syndrome
POTS in CFS

34

All five CFS patients analyzed were found
to have POTS

5

The hemodynamic and neurohumoral phenotype of postural tachycardia
syndrome
Characterizing POTS

231

Evidence is provided for increased
epinephrine & NE and impaired RAAS

Microvascular filtration is increased in postural tachycardia syndrome
80

13

Peripheral
vasoconstriction

Peripheral edema in POTS is due to
increased microvascular filtration

25

A multicenter study on treatment of autonomous nerve-mediated syncope in
children with beta-receptor blocker
Treatment with beta
receptor blocker

Metoprolol reduced symptoms in 68.75%
of POTS patients

54

56
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Reducing Rates of Misdiagnosis for Postural Orthostatic Tachycardia Syndrome Health
Questionnaire

Participation in this study is completely voluntary. If you choose to participate,
identifying information will not be collected. Vital signs (heart rate and blood
pressure) will be used for research purposes only. Thank you for your time.
Sex: ☐Female ☐Male

Age: ☐18-29 ☐30-39 ☐40-49

Have you experienced any of the following symptoms for longer than six
consecutive months? (Check all that apply)
☐Excessive fatigue

☐Lightheadedness

☐Shortness of
breath

☐Difficulty
standing still

☐Nausea/GI
discomfort

☐Reddish-blue
limbs

☐“Brain Fog”

☐Heart
palpitations

☐Numbness

☐Headache

☐Inability to
tolerate heat

☐Inability to
tolerate
exercise

☐Passing out

☐Feeling faint

☐Weakness

☐Feeling shaky

☐Need to drink excessive water
_____________________________
Supine (5 minutes)
Heart Rate: __________ bpm
Blood Pressure: ___________

☐Do not feel refreshed after sleep

The below section is for
researcher use only

_______________________________

Standing (immediate) Heart
Rate: __________ bpm
Blood Pressure: ___________

Standing (2 minutes)
Heart Rate: __________ bpm
Blood Pressure: ___________

Final Heart Rate Increase: ____________________
Significant BP decrease? ☐Yes ☐No
Potential POTS Candidate? ☐Yes ☐No

An increase in heart rate of 30 bpm or more without a large drop in
blood pressure indicates an individual is at risk for having POTS.
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